No photo of Luca Richeldi

Luca Richeldi

20182020
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Luca Richeldi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
Idiopathic Pulmonary Fibrosis Medicine & Life Sciences
Vital Capacity Medicine & Life Sciences
Pulmonary Fibrosis Medicine & Life Sciences
Interstitial Lung Diseases Medicine & Life Sciences
Lung Medicine & Life Sciences
Fibrosis Medicine & Life Sciences
Placebos Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2018 2020

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

Richeldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., Peony Yu, K-H., Neff, T., Porter, S., Zhong, M., Gorina, E., Kouchakji, E. & Raghu, G., Jan 2020, In : The Lancet Respiratory Medicine. 8, 1, p. 25-33 9 p.

Research output: Contribution to journal › Article

Connective Tissue Growth Factor
Idiopathic Pulmonary Fibrosis
Placebos
Vital Capacity
Therapeutics

Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients

Bianco, A., Mari, P-V., Larici, A. R., Lucchini, M., Nociti, V., Losavio, F. A., De Fino, C., Cicchetti, G., Coraci, D., Richeldi, L. & Mirabella, M., Oct 15 2019, In : Multiple Sclerosis and Related Disorders. 37, p. 101450

Research output: Contribution to journal › Article

Lung Injury
Multiple Sclerosis
Learning
Pneumonia
Adult Respiratory Distress Syndrome

Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis

Hill, C., Li, J., Liu, D., Conforti, F., Brereton, C. J., Yao, L., Zhou, Y., Alzetani, A., Chee, S. J., Marshall, B. G., Fletcher, S. V., Hancock, D., Ottensmeier, C. H., Steele, A. J., Downward, J., Richeldi, L., Lu, X., Davies, D. E., Jones, M. G. & Wang, Y., Aug 7 2019, In : Cell death & disease. 10, 8, p. 591

Research output: Contribution to journal › Article

Idiopathic Pulmonary Fibrosis
Epithelial-Mesenchymal Transition
Myofibroblasts
Pulmonary Fibrosis
Autophagy

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis

Wu, X., Kim, G. H., Salisbury, M. L., Barber, D., Bartholmai, B. J., Brown, K. K., Conoscenti, C. S., De Backer, J., Flaherty, K. R., Gruden, J. F., Hoffman, E. A., Humphries, S. M., Jacob, J., Maher, T. M., Raghu, G., Richeldi, L., Ross, B. D., Schlenker-Herceg, R., Sverzellati, N., Wells, A. U. & 4 others, Martinez, F. J., Lynch, D. A., Goldin, J. & Walsh, S. L. F., Jan 1 2019, In : American Journal of Respiratory and Critical Care Medicine. 199, 1, p. 12-21 10 p.

Research output: Contribution to journal › Article

Current and Future Idiopathic Pulmonary Fibrosis Therapy

Richeldi, L., Baldi, F., Pasciuto, G., Macagno, F. & Panico, L., May 2019, In : American Journal of the Medical Sciences. 357, 5, p. 370-373 4 p.

Research output: Contribution to journal › Review article

Idiopathic Pulmonary Fibrosis
Therapeutics
Drug Design
Disease Progression
Randomized Controlled Trials